Replimune Group, Inc. (REPL)
12.24
-0.83
(-6.35%)
USD |
NASDAQ |
Oct 13, 14:27
Replimune Group Net Income (Quarterly) : -69.77M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -69.77M |
| March 31, 2026 | -73.22M |
| December 31, 2025 | -70.93M |
| September 30, 2025 | -83.10M |
| June 30, 2025 | -86.69M |
| March 31, 2025 | -74.13M |
| December 31, 2024 | -66.34M |
| September 30, 2024 | -53.06M |
| June 30, 2024 | -53.77M |
| March 31, 2024 | -55.08M |
| December 31, 2023 | -51.12M |
| September 30, 2023 | -60.04M |
| June 30, 2023 | -49.56M |
| March 31, 2023 | -49.24M |
| December 31, 2022 | -39.69M |
| September 30, 2022 | -43.10M |
| June 30, 2022 | -42.25M |
| March 31, 2022 | -31.70M |
| December 31, 2021 | -29.67M |
| Date | Value |
|---|---|
| September 30, 2021 | -29.36M |
| June 30, 2021 | -27.31M |
| March 31, 2021 | -21.50M |
| December 31, 2020 | -21.78M |
| September 30, 2020 | -20.10M |
| June 30, 2020 | -17.49M |
| March 31, 2020 | -15.79M |
| December 31, 2019 | -16.19M |
| September 30, 2019 | -11.14M |
| June 30, 2019 | -9.508M |
| March 31, 2019 | -6.656M |
| December 31, 2018 | -7.673M |
| September 30, 2018 | -6.461M |
| June 30, 2018 | -10.04M |
| March 31, 2018 | -6.848M |
| December 31, 2017 | -4.354M |
| September 30, 2017 | -4.66M |
| June 30, 2017 | -3.552M |
| March 31, 2017 | -3.865M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Kalaris Therapeutics, Inc. | -11.52M |
| Arrowhead Pharmaceuticals, Inc. | -178.92M |
| Oncolytics Biotech, Inc. | -9.442M |
| Sangamo Therapeutics, Inc. | -31.00M |
| Sarepta Therapeutics, Inc. | -4.89M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 69.77M |
| EPS Diluted (Quarterly) | -0.7202 |
| Enterprise Value | 1.014B |
| Earnings Yield | -26.79% |
| Normalized Earnings Yield | -26.79 |